Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-18

Clinical Trial Update: A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation [Phase 1]

View source ↗

Summary

This Phase 1 study compared the bioavailability of LGD-6972 when administered as a capsule versus an oral solution.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LGD-6972

Snippet

Sponsor: Ligand Pharmaceuticals | Conditions: Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Status: COMPLETED